logo
logo

Receptor Life Sciences Secures $9.7 Million Financing To Advance Rls103 (Inhaled Dry Powder Cbd) Into Clinical Trials

Receptor Life Sciences Secures $9.7 Million Financing To Advance Rls103 (Inhaled Dry Powder Cbd) Into Clinical Trials

04/07/22, 12:00 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgseattle
Money raised
$9.7 million
Receptor Life Sciences (RLS), a pharmaceutical company developing innovative therapies to address central nervous system disorders, today announced the closing of a $9.7 million Series A-1 financing. The financing was led by Granite Point Capital, with participation from existing Series A and a syndicate of new investors.

Company Info

Company
Receptor Life Sciences
Location
seattle, washington, united states
Additional Info
Receptor Life Sciences is a pharmaceutical company that applies FDA-approved drug delivery technologies to develop innovative therapies to address central nervous system disorders that have few safe and effective treatments. Receptor Life Sciences uses these technologies to produce inhaled and oral cannabinoid products that hold the potential to provide precision, consistency, reliability, and convenience. For more information about Receptor Life Sciences, its patented product candidates and its progress toward FDA approval, see www.receptorlife.com.